Adjuvax attended the 2025 World Vaccine Congress in Washington DC as a startup biotech company.
Adjuvax has been granted The National Institutes of Health SBIR Phase II award for the continued discovery and
development of our saponin-based adjuvants.
In 2024, Adjuvax received a second Innovate Alabama Supplemental Grant.
In 2023, Adjuvax won the Start-Up of the Year Award from UAB Bill L. Harbert Institute for Innovation and Entrepreneurship.
In 2023, Adjuvax received an Innovate Alabama Supplemental Grant.
Read more here!
In 2022, Adjuvax secured two NIH SBIR Phase I awards for saponin adjuvant development.
At Adjuvax, we are dedicated to developing potent, cost-effective, structurally defined, and highly accessible saponin adjuvants with diverse activity profiles tailored to various vaccine applications.
Stay Connected: